Gainers

• Tivic Health Systems TIVC shares rose 127.3% to $0.59 during Friday's pre-market session. The market value of their outstanding shares is at $3.6 million.
• Doximity DOCS stock moved upwards by 39.82% to $60.71. The market value of their outstanding shares is at $11.2 billion. As per the news, the Q2 earnings report came out yesterday.
• Xilio Therapeutics XLO stock moved upwards by 14.42% to $1.19. The market value of their outstanding shares is at $52.3 million. As per the news, the Q3 earnings report came out yesterday.
• Eyenovia EYEN shares increased by 13.97% to $0.55. The market value of their outstanding shares is at $47.4 million.
• Fortrea Holdings FTRE shares rose 13.68% to $20.52. The market value of their outstanding shares is at $1.8 billion. The company's, Q3 earnings came out today.
• CytomX Therapeutics CTMX shares moved upwards by 12.99% to $1.13. The market value of their outstanding shares is at $88.2 million. As per the news, the Q3 earnings report came out yesterday.

Losers

• ProPhase Labs PRPH shares declined by 51.0% to $0.7 during Friday's pre-market session. The market value of their outstanding shares is at $13.3 million.
• Evolent Health EVH stock decreased by 35.5% to $15.85. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday.
• Agilon Health AGL shares fell 31.9% to $1.9. The company's market cap stands at $781.8 million. As per the news, the Q3 earnings report came out yesterday.
• Maravai LifeSciences MRVI shares declined by 28.19% to $5.63. The market value of their outstanding shares is at $796.9 million. As per the news, the Q3 earnings report came out yesterday.
• Revance Therapeutics RVNC shares fell 15.23% to $4.9. The market value of their outstanding shares is at $510.4 million. As per the press release, Q3 earnings came out yesterday.
• AlloVir ALVR shares fell 14.42% to $0.84. The company's market cap stands at $96.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.